still alive and kicking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Could be dementia and he thinks he's already done all of these things.
ski,
Gil said "He stated that the reason for the delay is that he wants to take GSII off the pink sheets so we can trade on the Bulletin Board or the American Exchange. (JERSEY are you able to verify this?)
With as much trouble as they have filing anything at this time and using Jersey (who is unpaid but good help), how is Gil going to provide for the timely financial submittals required on the higher trading exchanges? The man shouldn't be using this excuse for delaying this stock trading. The man seems delusional to me but I hope to be proven wrong. I mean, we aren't on the pink sheets, we're not trading at all!!! For goodness sakes Gil, quit thinking home run and just try to get us on base.
Just honked my horn to make it complete! eom
OK, we have a drawer full of condoms so let's see some action. It's kind of like we have these suiters and they say "well, if it only had this or that then I would be interested", then they go back to the drawing board and add "this or that" and end up seeking the never attainable perfection for the forever almost satisfied customer. If they would at least get Bent Glass up and going then we would know they have a workable product in the real world. Maybe we will hear something about that or even something from Spain soon. It is good that they have the patents but patents don't mean that the product is a marketable one. We surely need some proof of of concept in the marketplace. ok, i'm done venting and going back into hibernation lest I go crazy watching this thing trickle sideways and down but rarely up.
New symbol = LDPP.pk - Yahoo message board gone - anyone have a link to it as I used to go through the main board but the message box is not present now.
Well, if they get the filing done and up and running before the end of the year then I may hang onto them. That seems like a reasonable amount of time given it was assumed they would be submitted anytime now. Otherwise, I will have to consider how much of a fool I am to continue to cling to the word of a man who seems to be sociopathic liar who will say anything to keep people having faith in him. I just hope that you get reimbursed for your time, seems you have a lot of that invested and I truly fear for your demise in this one. Good luck.
It has looked dim for a very long time. Nobody should be getting their hopes up here. Probably should clear out these worthless shares in December and claim the losses. JMO
No, and they need to go ahead and let this baby learn to walk. Just a little frustration here but still have my shares.
It is filed, when do you think they will remove it?
Good news and an unexpected honor being the prize is usually given to algae generators.
LDPH - London & Pacific Healthcare Issues Open Letter to Shareholders
Press Release
Source: London & Pacific Healthcare, Inc.
On Monday September 21, 2009, 7:00 am EDT
Companies:London Pacific Healthcare, Inc.
EL SEGUNDO, Calif.--(BUSINESS WIRE)--LONDON & PACIFIC HEALTHCARE, INC. (PINK SHEETS:LDPH - News) (FRANKFURT:EGU - News) Executive Chairman, Stuart Bruck, issues open letter to shareholders.
Dear Shareholders:
Throughout this past year, the Board of Directors, in conjunction with the management team, key investors, business partners, employees, and experienced market consultants, has explored a variety of alternatives for significantly increasing shareholder value. We have analyzed, at length, industry trends, market needs, revenue opportunities, and our own internal processes. The result of these conversations and extensive research was a Board-wide understanding: we must branch out into additional industries in order to capture additional profits to optimize shareholder value.
Through our recent acquisition of Acadia Group Advisors, and our partnership with Harrell Hospitality Group, we have entered into two new market segments: (1) financial services, and (2) hospitality. We have also decided to change our company name to London Pacific & Partners, Inc. to reflect the broadening of our focus to these two additional business sectors. This name change will occur shortly. We are continuing to examine additional cash-generative partnership possibilities for entry into additional, complementary market segments, as we believe it is in the best interest of the company and our shareholders to explore all intelligent ways in which to increase our profits and, thereby, our value to you.
Our short term and long term goals involve several strategic options for increasing shareholder value. A primary focus for us in the short term is our share price. We firmly believe that our stock price today is grossly undervalued. In response, we are in the process of developing an internal investor/ media relations program, with the objectives of increasing our visibility amongst long-term, loyal investors and introducing the Company to new investors. We are also redesigning our website to be more informative to current and potential investors, and congruent with our recently expanded operations. The new website will be available soon.
Last week, we hired a fund raiser to obtain the necessary capital to file our Form 10, so that we may start trading on a higher exchange platform, such as AMEX or NASDAQ. We have already begun the internal process of gathering the historical financial data so that when the funds are successfully raised, we are prepared to promptly file our Form 10.
In the long term, we intend to continue to deliver profitable results, albeit on a greater scale due to our recent accretive acquisitions and potential future partnerships. We believe we serve our shareholders best by reinvesting our earnings into our business to maximize our growth; we will continue to do this. We are intently focused on growing our business, and will continue to strive to increase shareholder value through significant, profitable transactions.
With warmest regards,
Stuart Bruck
Executive Chairman
London& Pacific Healthcare, Inc.
About London & Pacific Healthcare, Inc.:
With offices in Los Angeles, Salt Lake City, London and Mumbai, London & Pacific Healthcare, Inc. is an international private equity and corporate finance investor and advisor focused on the transformation of undervalued and growth companies in the healthcare, hospitality, and financial services sectors. The Company’s website address is www.lphealthcare.com.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.
Contact:
Acadia Group, Inc.Investor RelationsDana M. Smith801-580-1901ir@acadiagrp.com Buzz up! 0
The recent "prototype biomass generator " looks like it has a combustion source as well as the WHE. That is what I am talking about, the new system just PR'd. It will have emissions depending on what is burned.
London & Pacific Healthcare Issues Open Letter to Shareholders
Press Release
Source: London & Pacific Healthcare, Inc.
On Monday September 21, 2009, 7:00 am EDT
Companies:London Pacific Healthcare, Inc.
EL SEGUNDO, Calif.--(BUSINESS WIRE)--LONDON & PACIFIC HEALTHCARE, INC. (PINK SHEETS:LDPH - News) (FRANKFURT:EGU - News) Executive Chairman, Stuart Bruck, issues open letter to shareholders.
Dear Shareholders:
Throughout this past year, the Board of Directors, in conjunction with the management team, key investors, business partners, employees, and experienced market consultants, has explored a variety of alternatives for significantly increasing shareholder value. We have analyzed, at length, industry trends, market needs, revenue opportunities, and our own internal processes. The result of these conversations and extensive research was a Board-wide understanding: we must branch out into additional industries in order to capture additional profits to optimize shareholder value.
Through our recent acquisition of Acadia Group Advisors, and our partnership with Harrell Hospitality Group, we have entered into two new market segments: (1) financial services, and (2) hospitality. We have also decided to change our company name to London Pacific & Partners, Inc. to reflect the broadening of our focus to these two additional business sectors. This name change will occur shortly. We are continuing to examine additional cash-generative partnership possibilities for entry into additional, complementary market segments, as we believe it is in the best interest of the company and our shareholders to explore all intelligent ways in which to increase our profits and, thereby, our value to you.
Our short term and long term goals involve several strategic options for increasing shareholder value. A primary focus for us in the short term is our share price. We firmly believe that our stock price today is grossly undervalued. In response, we are in the process of developing an internal investor/ media relations program, with the objectives of increasing our visibility amongst long-term, loyal investors and introducing the Company to new investors. We are also redesigning our website to be more informative to current and potential investors, and congruent with our recently expanded operations. The new website will be available soon.
Last week, we hired a fund raiser to obtain the necessary capital to file our Form 10, so that we may start trading on a higher exchange platform, such as AMEX or NASDAQ. We have already begun the internal process of gathering the historical financial data so that when the funds are successfully raised, we are prepared to promptly file our Form 10.
In the long term, we intend to continue to deliver profitable results, albeit on a greater scale due to our recent accretive acquisitions and potential future partnerships. We believe we serve our shareholders best by reinvesting our earnings into our business to maximize our growth; we will continue to do this. We are intently focused on growing our business, and will continue to strive to increase shareholder value through significant, profitable transactions.
With warmest regards,
Stuart Bruck
Executive Chairman
London& Pacific Healthcare, Inc.
About London & Pacific Healthcare, Inc.:
With offices in Los Angeles, Salt Lake City, London and Mumbai, London & Pacific Healthcare, Inc. is an international private equity and corporate finance investor and advisor focused on the transformation of undervalued and growth companies in the healthcare, hospitality, and financial services sectors. The Company’s website address is www.lphealthcare.com.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.
Contact:
Acadia Group, Inc.Investor RelationsDana M. Smith801-580-1901ir@acadiagrp.com Buzz up! 0
Have they made their emissions test results public on the WHE? Is the testing adequate (meeting EPA emission testing standards) to provide industrial facilities the numbers they need to assure compliance with emission standards at their plant?
are we there yet?
I agree, the expense is there and supposes a good turn in economic events by the company. I hope the perception becomes reality.
Don't know arnold, seems the telegraph and the telephone had several prototypes before the one that actually made it to the market first. This is the nature of invention, I'm afraid.
good find kat, gl
AIS - Antares Pharma Announces Launch of Tjet Needle-Free Injector System by Marketing Partner Teva
Press Release
Source: Antares Pharma, Inc.
On Tuesday August 25, 2009, 8:00 am EDT
Companies:Antares Pharma Inc.
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS) today announced that its partner Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA - News) has launched its new Tjet™ needle-free injector system for the administration of human growth hormone (hGH). The Tjet™ device will be available exclusively in combination with the Teva hGH product Tev-Tropin® [somatropin (rDNA) for injection].
Robert F. Apple EVP, CFO and President of the Parenteral Products Division stated, “We are pleased that this product is now commercially available in the United States for children with growth hormone deficiency in a convenient, more user-friendly format and marks the first product launched under our strategic collaboration with Teva. We look forward to growing our business through additional product sales and royalty revenue with the launch of the Tjet device.”
Human growth hormone is a protein given by injection that is commonly used to treat children with growth hormone deficiency. Pediatric patients benefit both from the avoidance of using needles as well as the rapid injection speed associated with giving needle-free injections. According to industry estimates, the market for human growth hormone in the United States is approximately $1 billion which is the largest market segment globally. Antares currently markets its needle-free injection system for use in the treatment of growth hormone deficient children through its partners in Europe, Japan and Asia.
About Antares Pharma (www.antarespharma.com)
Antares Pharma is a product development company committed to improving pharmaceuticals through its patented drug delivery systems. Antares has multiple development partnerships with leading pharmaceutical companies. The Company’s products are designed to improve safety and efficacy profiles by minimizing dosing and reducing side effects while enabling improved patient compliance. Antares has three validated drug delivery systems: the ATDTM Advanced Transdermal Gel Delivery system, injection technology platforms including both VibexTM disposable pressure assisted auto injectors and Vision® reusable needle-free injectors; and Easy TecTM oral disintegrating tablets (ODT). Two of the systems have generated FDA approved products. Antares Pharma leverages its multiple drug delivery systems to add value to existing drugs and to create new products. Antares Pharma has corporate headquarters in Ewing, New Jersey, with subsidiaries performing research, development, manufacturing and product commercialization activities in Minneapolis, Minnesota and Basel, Switzerland.
About Teva
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world's leading generic pharmaceutical company. The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Over 80 percent of Teva's sales are in North America and Europe.
Antares’ Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements related to the Company’s future financial performance, and other statements which are other than statements of historical facts. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expects," "intends," "plans," anticipates," "believes," "estimates," "predicts," "projects," "potential," "continue," and other similar terminology or the negative of these terms, but their absence does not mean that a particular statement is not forward-looking. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others statements that the Company looks forward to growing its business through additional product sales and royalty revenue with the launch of the Tjet system.
Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
Contact:
Contacts:Antares Pharma, Inc.Robert F. Apple, 609-359-3020orIn-Site Communications, Inc.Lisa M. Wilson, 917-543-9932lwilson@insitecony.com Buzz up! 0
Agreed, independent 3rd party testing would provide a better "resume" for this engine. I guess that some "third party" testing is being done by the Solar company and others working on the sidelines (darpa, etc) but also in conjunction with cypw engineers. I suspect a true 3rd party independent test would be costly at this juncture but it should be in the play book going forward. jmo
That would be what we need to get this company on the map. Only hope it happens sooner than later.
shhhhhhh, don't wake him back up! lol
you go grajekk, that ought to give us a pop!
another dynamometric success story!! errr ... is anybody buying it?
There is no "supposed to" with this stock. This company does not trade easily (for example .. AT members must call it in and can't do it automatically on-line). It's float is fairly low and it is not one for day traders to flock since they can't get in and out very easily. I was totally expecting no reaction to this news as it is under most people's radar. Personally, I don't mind if it stays that way for a while.
Here's a link to the full report:
http://www.pinksheets.com/otciq/ajax/showFinancialReportById.pdf?id=23281
I contacted the company to see why the share count was not up to date as of the end of June. Will let you know if I get a response. Also requested some discussion on recent acquisitions via a note to shareholders .. maybe they will let us know a little more?
gl
Have done well with neph ctic and hope to do well with ggox (suggest taking a look at ggox ... it is very low float so not easy to get in and out of but I think it will do well long term ... earnings are after close of market today so wait to see what happens after that. I got into neph around .7 and I think it will pop over 2 with two nda approvals coming up soon ... at least we assume they will be approved .. if not, she goes down ... it has gotten a bit pricey in the last couple of days so not sure what is going on there. I may take a little off the table there and preserve some gains). I am also dabbling in this little stock ldph ... interesting and could be a big gainer if they get off the pinks as they just promised to do in the latest PR following an acquisition. Given my track record (aka .. i did invest in gsii) I would take what I say very warily but I am riding on success lately so am feeling a bit better.
Anybody have anything going worth sharing while we wait for this one? The less pink the better!
Well, you are not crazy and I can assure you that if this company is not back up and running before the end of December my shares will be eliminated into the AT trashpile and I will be using my losses to offset my gains this year for tax purposes. I am done with being upset over Gil and this company's demise and pretty much just hanging on til the last minute because it's the only thing that makes sense economically. Odds are we will not rise from the ashes but there is always a first time in the history of pinks and riding on the cusp of history is what this is all about! Besides, it is sometimes nice to keep in touch with some of these folks on this board as we all have a sense of humor about our situation here.
London & Pacific Completes Acquisition of Acadia Group Advisors
Press Release
Source: London & Pacific Healthcare, Inc.
On Wednesday August 12, 2009, 7:00 am EDT
Companies:London Pacific Healthcare, Inc.
EL SEGUNDO, Calif.--(BUSINESS WIRE)--LONDON & PACIFIC HEALTHCARE, INC. (PINK SHEETS:LDPH - News) (FRANKFURT:EGU - News) (“London & Pacific” or the “Company”), the international advisory and management specialist, today announced the successful completion of the acquisition of Acadia Group Advisors, Inc. (“Acadia”), a privately-held international corporate financier and private equity advisor.
The principals of Acadia, in their predecessor company, Acadia Group, Inc., completed numerous transactions in 2008, resulting in revenue of $1.5 million and operating profit of $750,000. Current financial performance of Acadia for 2009 is consistent with that of 2008.
In accordance with the previously announced terms of the transaction, London & Pacific acquired all of the outstanding shares of Acadia in exchange for 20 million shares of London & Pacific common stock and 10 million 7-year warrants at a strike price of $0.20 each. London & Pacific believes Acadia will create immediate and long-term shareholder value.
Acadia will be functioning as the execution arm for London & Pacific’s corporate finance transactions worldwide, and is expected to significantly accentuate the profitability of the Company by working on existing projects, as well as finding, structuring, and negotiating future deals. Acadia’s first post-acquisition task is to list London & Pacific on one or more quotation mediums with higher investor market visibility, such as NASDAQ.
Stuart Bruck, Chairman and CEO of London & Pacific, stated, “We have long been impressed with Acadia, the reputation of its capabilities, its profitable operating history, and the caliber of its management team. Together, our organizations are a good fit strategically, financially and operationally. Our acquisition of Acadia will undoubtedly capitalize on the ever-increasing market need for professional advisory services and execution capabilities across overlapping industry specialties. This immediately-accretive acquisition provides us with a strengthened balance sheet, administrative cost savings, including reduced legal, audit and overhead costs, and an experienced team that can focus on the development and expansion of our company.”
Newly-appointed Deputy Executive Chairman of London & Pacific, and President of US-based Acadia Group Advisors, Kenneth I. Denos, stated, “We look forward to bringing operational and cost efficiencies to London & Pacific, while working together as strategic partners in promoting the growth and financial success of the Company. The combination of our businesses will create a stronger, leaner force in the advisory market with more opportunities for increased shareholder value through increased revenues and operational profits.”
From August 2007 to June 2009, Mr. Denos was the President and Chief Executive Officer of Equus Total Return, Inc. (NYSE:EQS - News), a closed-end fund traded on the New York Stock Exchange. Mr. Denos was also the Executive Vice President of Equus from June 2005 to August 2007. From May 2006 to July 2009, he was the CEO of MCC Global NV (FSE:IFQ2) an international financial services and investment conglomerate based in London and traded on the Frankfurt Stock Exchange. For more than a decade, Mr. Denos has served as a director or principal for several small-cap public companies on the London AIM and the OTC Bulletin Board. Mr. Denos holds a Master of Business Administration and a Juris Doctorate from the University of Utah.
About London & Pacific Healthcare, Inc.:
With offices in Los Angeles, London and Mumbai, London & Pacific Healthcare, Inc. is an international advisory and management specialist. The Company’s website address is www.lphealthcare.com.
About Acadia Group Advisors, Inc.:
Acadia Group Advisors is an international corporate finance and private equity advisor that specializes in investment portfolio management and transaction execution. Acadia’s team of experienced professionals has advised and managed a wide variety of complex public and private financial transactions in multiple geographic areas and industries.
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.
Contact:
Acadia Group, Inc.Investor RelationsDana M. Smith801-816-2568ir@acadiagrp.com
Based on today's news, it looks like the exclusivity agreement includes the burning of waste oil. This is good and does not limit expansion into other types of fuel uses. Just my read on it.
OK, so the onus is on someone else and we get some money. Sounds good to me. Just from my experience with air regulations, I expect royalties to be minimal as burning waste oil will probably require controls or won't be permitted at all. I have to question the "exclusivity" option and whether that is limited to their engine burning waste oil. Otherwise, it sounds like they may have backed themselves into a corner. Hopefully, the exclusive language includes the burning of waste oil so that Cyclone can license its engine to other companies with more potential for expansion and more royalties.
Thanks Kat!
Agree, but do need audited financial reports to give them stature. Concerning pink sheet stocks, this one has one of the most thorough unaudited financial reports that I have seen and has kept me interested in their growth. The OS and float will go up with their latest acquisition but it is still pretty low. I expect we will see financials in about 2 or 3 weeks if they come out as timely as they have in the past. I could not find much information on the company they acquired through my searches so not sure what we have here yet.
rags
been gone for a week and just saw this PR. Right now, many industrial sites have been refused permits to burn waste oil due to the hazardous air pollutants, particularly metals, that are found in used oil. I am wondering how this will be permitted. I suspect there will need to be some performance tests before this will be allowed in real life. Just an observation based on industry's experience with trying to get rid of waste oil in ways other than manifesting it through the hazmat route. Anyone who has contact with the company be willing to ask this question?
rags
uplisting will be critical to make this company appear legit to the marketplace. Hope it happens before the end of the year.
Be interesting to see what the company has up its sleeves concerning acquisitions and how smartly they go about it.
London & Pacific Healthcare CEO Announces Expanded Vision for Company Strategic Acquisitions and Expanded Service Capabilities Are Expected
Press Release
Source: London & Pacific Healthcare, Inc.
On Thursday July 30, 2009, 7:00 am EDT
EL SEGUNDO, Calif.--(BUSINESS WIRE)--LONDON & PACIFIC HEALTHCARE, INC. (PINK SHEETS: LDPH - News) (FRANKFURT: EGU - News) (“London & Pacific” or the “Company”), the international healthcare advisory specialist, today announced that it intends to broaden its core healthcare advisory and investment focus to include corporate finance, hospitality and other strategically complementary sectors.
Chairman and CEO Stuart Bruck stated, "London & Pacific has advised healthcare service firms internationally for over three years, participating in a variety of profitable projects during that time. Our engagements and projects are often paired with additional revenue opportunities that require non-healthcare related expertise, such as a hospital expansion project coupled with real estate development and/or leaseback financing.
"Although these projects require execution capabilities in a number of industry sectors, most advisory firms are not qualified to manage such opportunities because they lack experience in the overlapping industry specialties.
"We recognize that there are tremendous revenue-earning opportunities in corporate finance and non-healthcare related advisory engagements that present themselves to us because of our experience and relationships with senior executives. To that end, London & Pacific is actively seeking to broaden its service offering to capture a wider array of high-value transactions, increase its revenues and profitability, and grow shareholder value.
"Expanding our service capabilities into complementary industries ensures our clients a cost-effective and integrated solution to their overlapping industry needs. In turn, our access to revenue-producing projects is greatly increased due to our ability to service clients across multiple industries."
London & Pacific is considering several strategic acquisitions in complementary industry sectors for a greater diversity of revenue streams, increased profitability, and the various service capabilities the acquisitions would necessarily contribute. The Company is currently involved in advanced discussions with two entities regarding near-term acquisition of their respective businesses.
London & Pacific expects both its revenues and profits to respond positively to this new direction due to increased efficiencies in its current businesses, as well as any acquisitions; shared use of facilities; current contracts that require industry specialization outside of the healthcare realm into which acquisitions can readily assume responsibilities; and the centralization of its regulated corporate finance functions in the US, UK and worldwide.
Commenting further on the Company’s growth, Mr. Bruck stated, "I am pleased and confident with this expanded approach. Our capability to evolve in response to great market demand is testament to one of our company's greatest strengths: our ability to create profitable, cost-effective solutions for company growth. This service expansion should provide us with improved access to high-value projects. It should also significantly broaden our client base and increase shareholder value from diversified revenue streams and greater profits."
This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development acceptance, and the impact of competitive services and pricing and general economic risks and uncertainties.
Contact:
Acadia Group, Inc.Dana M. Smith, Investor Relations801-816-2568ir@acadiagrp.com
Not bad ski, plenty busy and had the joy of having our daughter live with us for a couple of months between her job in DC and med school. I dropped about 10 lbs as she is a health and physical fitness nut ... that healthy eating stuff is killing me! I try to be appreciative though when someone else is making me something to eat. The stuff I cook involves playing with fire. Hope yours is going well. I still like Penny's idea of paying off gsii lawyers and others with company stock. Very motivating to get us back to trading.
thanks skibum, won't get into any jokes about "Gil time" and how long that translates but am glad he called you back and you spoke with him. Appreciate the update.
Yes, there are a couple of us watching (and have shares) in this one. We post mostly on the yahoo board. This board is not being managed.